SOX Sequential S-1 in Advanced Biliary Tract Carcinoma（BTC）and Pancreatic Cancer

Sponsor

Peking University (Other)

Overall Status

Unknown status

CT.gov ID

NCT01811277

Collaborator

Taiho Pharmaceutical Co., Ltd. (Industry)

Enrollment

Location

Arm

Duration (Months)

0.8

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is an exploratory, single-armed, open label study on the efficacy and safety of sequential S-1 therapy after SOX in unresectable metastatic or locally advanced biliary system or periampullary cancer or pancreatic cancer patients. The primary endpoint is Objective response rate and secondary endpoint is progression free survival , overall survival ,1 year survival rate and safety.

Condition or Disease	Intervention/Treatment	Phase
Biliary Tract Cancer Periampullary Adenocarcinoma Pancreatic Cancer	Drug: SOX sequential S-1	Phase 2

Study Design

Study Type:

Interventional

Anticipated Enrollment :

40 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Phase II Exploratory Study of S-1 Combined With Oxaliplatin Sequential S-1 Single-agent First-line Treatment of Unresectable Metastatic or Locally Advanced Biliary System, Periampullary Cancer and Pancreatic Cancer

Study Start Date :

Jul 1, 2010

Anticipated Primary Completion Date :

Jul 1, 2014

Anticipated Study Completion Date :

Jul 1, 2014

Arms and Interventions

Arm	Intervention/Treatment
Experimental: SOX sequential S-1 4-6 cycles of SOX followed by S-1 monotherapy until disease progression	Drug: SOX sequential S-1 4-6 cycles SOX followed by S-1 monotherapy until disease progression S-1: 40~60mg bid，po, d1~14 （S-1：BSA <1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA>1.5m2, 60mg bid） oxaliplatin：130mg/m2，iv drip for 2h，d1 Other Names: S-1/oxaliplatin

Arm

Intervention/Treatment

Experimental: SOX sequential S-1

4-6 cycles of SOX followed by S-1 monotherapy until disease progression

Drug: SOX sequential S-1

4-6 cycles SOX followed by S-1 monotherapy until disease progression S-1: 40~60mg bid，po, d1~14 （S-1：BSA <1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA>1.5m2, 60mg bid） oxaliplatin：130mg/m2，iv drip for 2h，d1

Other Names:

S-1/oxaliplatin

Outcome Measures

Primary Outcome Measures

Objective response rate for SOX sequential S-1 [1 years]
The primary endpoint is objective response rate,which equals CR+PR.

Secondary Outcome Measures

Overall Survival [2 years]
OS means that from the first dose of treatment drug to death or lost, the follow-up visit will be performed every 3 months till death or lost
progression free survival [1 year]
PFS means that from the first dose of treatment drug to disease progression or death or lost, the follow-up visit will be performed every 6 weeks till progression or death or lost
1 year survival rate [1 year]
the follow-up visit of survival will be performed every 3 months till 1 year
Number of Participants with Adverse Events as a Measure of Safety and Tolerability [2 years]
participants will be followed for the duration of hospital stay, an expected average of 3 weeks

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 75 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Written Informed consent
Male or female patients >=18 years old
Histologically or cytologically confirmed diagnosis of adenocarcinoma
No previous treatment is allowed including chemotherapy, radiotherapy,immunotherapy or others.
In case the patient received adjuvant therapy before, enrollment is allowed if the adjuvant therapy does not contain L-OHP or S-1 and at the same time, the last day of chemotherapy is ≥180 days before screening.
Target lesion more than 1cm in diameter by enhanced CT or MRI 21 days before enrollment
The laboratory parameter meets the following criteria 7 days before enrollment
Hemoglobin ≥90g/L
Absolute neutrophil count≥1.5×10^{9/L, platelets 100×10}9/L；
ALT and AST≤2.5 ULN(in case of the patients with liver metastasis,ALT and AST≤5.0 ULN)
ALP ≤2.5 ULN (in case of the patients with liver metastasis,≤5.0 ULN)
Total Serum bilirubin ≤1.5 ULN
Serum creatinine ≤1.0 ULN
serum albumin(ALB)≥30g/L；
can tolerate oral drug administration；
KPS ≥70
Estimated survival ≥90 days
Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days of enrollment and must be willing to use adequate methods of contraception during the study and for 30 days after last study durg administration.

Exclusion Criteria:

Known sensitivity to 5-HT3 antagonist and hypersensitivity to the other treatment agents including irinotecan, cisplatin and octreotide lar
Any participation in trials simultaneously or 4 weeks before screening.
15 days prior to enrollment, received a blood transfusion, blood products and hematopoietic growth factors such as G-CSF.
Undergone major surgery ≤ 4 weeks prior to starting study drug or who have not recovered from side effects of such surgery.
Uncontrolled severe diarrhea
Uncontrolled active infection (fever ≥38 degrees due to infection)
S-1 oral drug administration difficulty due to difficulty swallowing, complete or incomplete digestive tract obstruction, gastrointestinal active bleeding, perforation;
severe hepatopathy including active hepatitis and hepatic cirrhosis, renal dysfunction, severe pulmonary diseases including interstitial pneumonia, pulmonary fibrosis and severe pulmonary emphysema, uncontrolled diabetes, hypertension and other chronic systematic diseases.
Chronic treatment with steroids.(In case of the patients with short-term use of steroids, the enrollment is permitted if the administration is stopped 2 weeks before screening.)
confirmed or suspected CNS metastasis
the history of peripheral nervous system impairment, obvious mental disorder or CNS impairment
clinically significant heart disease, including congestive heart failure, symptomatic coronal heart disease, arrythmia uncontrolled by medication and acute myocardial infarction or cardiac insufficiency within 6 months before screening
Drainage of pleural effusion, peritoneal effusion and pericardial effusion
pregnant women or women in lactation period
Fertile male or women of child-bearing potential refuse to take highly effective methods of birth control
Incidence of other second primary malignant tumors within 5 years, except for cured basal cell carcinoma and cervical carcinoma in situ.
patients of legal incapacity or who have the potential of influence the whole trial due to medical or ethic reasons.
Other patients who are not eligible to the trial under investigators' discretion